LOS ANGELES, CA, Dec. 28, 2017 — Endonovo Therapeutics, Inc. (OTCQB: ENDV) (“Endonovo” or the “Company”), a clinical-stage developer of non-invasive electroceuticals for the treatment of vascular diseases and inflammatory conditions, today provided an update on the acquisition of the PEMF assets from Rio Grande Neurosciences, its clinical pipeline targeting central nervous system disorders and its pre-clinical study on post-MI remodeling.The Company is currently in the process of transferring all of the assets it has acquired from Rio Grande Neurosciences and registering with the Food and Drug Administration to become regulatory compliant. These important steps must be completed in order for the Company to pursue the commercialization its tPEMF technology.Endonovo's pipeline in central nervous system (“CNS”) disorders includes currently planned clinical trials to evaluate its tPEMF therapy in post-concussion syndrome, acute sports-related concussion and an open label study to generate preliminary clinical data on adjunctive tPEMF therapy in patients with relapsing-remitting multiple sclerosis. The Company is seeking to further expand its clinical pipeline to evaluate its tPEMF therapy in ischemic stroke and other neurodegenerative diseases.The Company believes that its non-invasive technology has the potential to become standard care in the treatment of CNS disorders because its technology operates via induction (the generation of small electric currents in brain tissue) to quell neuroinflammation; promote neuroprotection and the formation of new blood vessels. The Company believes that its technology addresses the major setback limiting the development of treatments for CNS disorders, the blood-brain-barrier (BBB), which prevents the delivery of efficacious levels of drugs to the central nervous system (CNS). Unlike pharmaceutical-based treatments, the blood-brain-barrier cannot hinder the delivery of the Company's tPEMF therapy to the brain parenchyma, which is one of the major hurdles to the effective treatment of CNS disorders.Furthermore, the Company is finalizing the data on its pre-clinical study to assess the efficacy of its non-invasive electroceutical for the treatment and prevention of heart failure following myocardial infarction and will release the results early in the first quarter of 2018. Endonovo had previously released data from its pre-clinical study, which found treatment with the Company's non-invasive electroceutical two or three times per day resulted in significantly increased cardiac function and reduced ventricular remodeling. Treatment with the Company's Immunotronics™ technology two or three times per day resulted in significantly improved Ejection Fraction (EF), Fractional Shortening (FS), Heart Weight-to-Body Weight Ratio (HW/BW), Left Ventricular Diastolic Pressure (LVDP), Left Ventricular End-Systolic Diameter (LVESD), and Interventricular Septal Dimension at Systole (IVSS).
About Ischemic Stroke:Ischemic strokes occur because of an obstruction within a blood vessel supplying blood to the brain and accounts for about 87 percent of all strokes, according to the American Heart Association. According to the Centers for Disease Control and Prevention, about 800,000 new strokes occur in the United States each year. The total, direct medical stroke-related costs are expected to triple between 2012 and 2030 from $71.6 billion to $184.1 billion, according to the American Heart Association. There is currently only one FDA Approved treatment for ischemic stroke, which must be administered within three hours of stroke. However, according to the American Stroke Association, only 22 to 31 percent of acute ischemic stroke patients present themselves to the emergency department within 3 hours of the onset of symptoms. This hyper-acute treatment window means that individuals that experience a stroke during the night, alone, or in a rural area may have significant trouble in reaching the hospital in time and benefiting from this treatment.
About Targeted-Pulsed Electromagnetic Fields (tPEMF):Targeted-Pulsed Electromagnetic Fields (tPEMF) use radiofrequency waves at 27.12 MHz to deliver electromagnetic energy to tissues. The Company's tPEMF technology works by restoring key electrochemical process that initiate the anti-inflammatory and growth factor cascades necessary for healing to occur. tPEMF technology has been shown to accelerate the production of the endogenous constitutive nitric oxide synthase systems (cNOS): the anti-inflammatory system, resulting in increased blood and lymph flow, and decreased pain and edema.The Company's tPEMF technology has been evaluated in 5 randomized controlled clinical trials and has demonstrated significant reductions in pain, edema and use of pain medication.In pre-clinical studies of neuroinflammation and brain injury, the Company's tPEMF technology has demonstrated significant reduction of neuroinflammation, including a 5-fold reduction of IL-1 beta, a master regulator of neuroinflammation, when compared to untreated animals. Furthermore, in pre-clinical studies of angiogenesis (promotion of new blood vessels), the Company's tPEMF technology demonstrated a 500 percent increase in angiogenesis at 8 weeks.An Overview of the Company's tPEMF Technology can be found in the presentations page on the Investor Section of the Company's website.
About Endonovo TherapeuticsEndonovo Therapeutics, Inc. is a clinical-stage developer of non-invasive electroceuticals for the treatment of vascular diseases, including cardiovascular and cerebrovascular disease, and inflammatory conditions. The Company's non-invasive electroceuticals use targeted-Pulsed Electromagnetic Fields (tPEMF) to induce micro-currents in tissues to target proinflammatory, fibrogenic and regenerative signaling pathways for the treatment of cardiovascular and cerebrovascular diseases, as well as for the treatment of chronic kidney and liver disease. Endonovo Therapeutics' is developing a pipeline of electroceutical-based therapies for the treatment of cardiovascular disease, cerebrovascular disease, peripheral artery disease, chronic kidney disease, non-alcoholic steatohepatitis (NASH) and chronic wounds. The Company's tPEMF technology using short wave radiofrequency at 27.12 MHz has been FDA-cleared and has a CE Mark for the treatment of soft tissue injuries and post-operative pain and edema, as well as CMS National Coverage for the treatment of chronic wounds. Endonovo is developing a clinical pipeline using tPEMF for the treatment of central nervous system (CNS) disorders, including post-concussion syndrome, mild traumatic brain injury (mTBI), and multiple sclerosis.Safe Harbor StatementThis press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.Investors: Sign Up for Email Alerts on Endonovo
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Senior Vice President of Investor Relations
(800) 701-1223, Ext. 108
Powered by WPeMatico